Theragenics ($TGX) blames the "headwinds" of healthcare reform fallout, the looming medical device tax and economic uncertainty for a disappointing 2012 third quarter. The maker of surgical products and brachytherapy seeds for prostate cancer treatments said revenue and net income both declined.
The House of Representatives voted to repeal the Affordable Care Act once more, with Republicans saying that while the Supreme Court has upheld the law as constitutional, it is over-reaching and "job-killing" in regards to the medical device tax.
Along with the Supreme Court's decision that, for the most part, the Affordable Healthcare Act is constitutional has come a firestorm of analysis of what it means to drug companies going forward: more patients, but not as many as hoped, more fees, but those were already planned for.
House Republicans are continuing their anti-healthcare reform campaign with shots aimed at Big Pharma.
The cat is out of the bag so to speak with the disclosure of memos today detailing the level of drug industry support for passage of President Obama's prized healthcare reform.
If the healthcare reform bill gets shot down by the Supreme Court, pharma could pop into the cross hairs of politicians.
Washington Post columnist George F. Will says that, unless its repealed, the coming tax on devicemakers will lead to fewer jobs and less innovation.
The House Energy and Commerce Committee has demanded documents and information from five of the top pharma companies.
Two senators are pushing regulators to issue rules for complying with the doctor-disclosure provisions of healthcare reform.
As China's National People's Congress ends in Beijing, Chinese politicians are repeating their pledge to make healthcare more affordable.